Search

Your search keyword '"Zinman, B"' showing total 33 results

Search Constraints

Start Over You searched for: Author "Zinman, B" Remove constraint Author: "Zinman, B" Database OAIster Remove constraint Database: OAIster
33 results on '"Zinman, B"'

Search Results

1. Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.

2. Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.

3. Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME

4. Dapagliflozin and cardiovascular outcomes in type 2 diabetes

5. Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria a credence secondary analysis

6. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

7. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

8. Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study

9. Sex disparities in cardiovascular outcome trials of populations with diabetes: A Systematic Review and Meta-analysis

10. Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease

11. Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)

12. THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL

13. P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL

14. P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL

15. Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: Subgroup analysis of the randomized CREDENCE trial

16. The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial

17. Sex disparities in cardiovascular outcome trials of populations with diabetes: A Systematic Review and Meta-analysis

18. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: A secondary analysis of the CREDENCE randomized trial

19. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial

20. Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial

21. Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial

22. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial

23. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

24. Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial

25. Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial

26. The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics

27. Significance of epicardial and intrathoracic adipose tissue volume among type 1 diabetes patients in the DCCT/EDIC: A pilot study

28. Liraglutide and cardiovascular outcomes in type 2 diabetes

29. Maternal pregravid weight is the primary determinant of serum leptin and its metabolic associations in pregnancy, irrespective of gestational glucose tolerance status

30. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial

31. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial

32. International expert committee report on the role of the A1C assay in the diagnosis of diabetes

33. International expert committee report on the role of the A1C assay in the diagnosis of diabetes

Catalog

Books, media, physical & digital resources